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Introduction: Research has shown that eating disorder (ED) patients who abuse substances demonstrate worse ED
symptomatology and poorer outcomes than those with EDs alone, including increased general medical
complications and psychopathology, longer recovery times, poorer functional outcomes and higher relapse rates.
This article provides a broad overview of the prevalence, aetiology, assessment and management of co-morbid EDs
and substance use disorders (SUDs).
Review: The co-occurrence of EDs and SUDs is high. The functional relationship between EDs and SUDs vary within
and across ED subtypes, depends on the class of substance, and needs to be carefully assessed for each patient.
Substances such as caffeine, tobacco, insulin, thyroid medications, stimulants or over the counter medications
(laxatives, diuretics) may be used to aid weight loss and/or provide energy, and alcohol or psychoactive substances
could be used for emotional regulation or as part of a pattern of impulsive behaviour. A key message conveyed in
the current literature is the importance of screening and assessment for co-morbid SUDs and EDs in patients
presenting with either disorder. There is a paucity of treatment studies on the management of co-occurring EDs
and SUDs. Overall, the literature indicates that the ED and SUD should be addressed simultaneously using a
multi-disciplinary approach. The need for medical stabilization, hospitalization or inpatient treatment needs to be
assessed based on general medical and psychiatric considerations. Common features across therapeutic interventions
include psycho-education about the aetiological commonalities, risks and sequelae of concurrent ED behaviours and
substance abuse, dietary education and planning, cognitive challenging of eating disordered attitudes and beliefs,
building of skills and coping mechanisms, addressing obstacles to improvement and the prevention of relapse.
Emphasis should be placed on building a collaborative therapeutic relationship and avoiding power struggles.
Cognitive behavioural therapy has been frequently used in the treatment of co-morbid EDs and SUDs, however there
are no randomized controlled trials. More recently evidence has been found for the efficacy of dialectical behavioural
therapy in reducing both ED and substance use behaviours.
Conclusion: Future research would benefit from a meta-analysis of the current research in order to better
understand the relationships between these two commonly co-occurring disorders.* Correspondence: sseedat@sun.ac.za
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The understanding and management of eating disorders
(EDs) presents challenges to researchers and clinicians
alike. Complicating factors include patients’ reluctance
to seek treatment because of psychological investment in
maintaining the disorder, high rates of co-morbidity with
other Axis I and II disorders and variations in symptom
presentation and aetiological factors both within and
across ED subtypes [1-3]. Co-morbid substance use
disorder (SUD) is commonly found with EDs and can
lead to increased general medical complications and
psychopathology, longer recovery times, poorer func-
tional outcomes and higher relapse rates [4-7]. This
article considers the prevalence of co-morbid EDs
and SUDs, the types of substances used and their role
and function in ED pathology before outlining assess-
ment and diagnostic considerations and management
strategies.
Review
Epidemiology
Prevalence
The rates of co-morbid eating EDs and SUDs reported
in the literature are high. These rates do vary across
studies however, in part due to the heterogeneity of defi-
nitions of SUDs that have been applied. For example,
only some studies distinguish between substance use,
abuse and dependence or disorder. Studies have reported
that up to 50% of patients with an eating disorder will
abuse alcohol or an illicit substance, compared with 9%
of the general population, and that 35% of alcohol or
illicit substance abusers have an eating disorder where
the general population prevalence of an eating disorder
is 3% [8]. In a more recent review of the literature, rates
of between 17% and 46% were reported [7]. In adoles-
cent populations exhibiting eating disordered behaviour,
rates of substance use and abuse has also been found to
be 20-40% greater than that of normal weight peers [9].
Traditionally, Bulimia Nervosa (BN) has had the stron-
gest reported association with substance use compared
with Anorexia Nervosa (AN) [6,10-14]. In a meta-
analysis of the literature, Calero-Elvira et al. (2009) found
a “significant but negligible” increase in substance use
amongst those with an ED compared with healthy controls.
They reported the highest prevalence of substance
use in those with BN purging type followed by those
with Binge Eating Disorder (BED), compared with
the healthy population, whereas those with AN re-
stricting type had lower levels of drug use than healthy
controls [15].
However, some recent studies have documented that
co-morbid AN and SUDs may be more prevalent than
previously thought, particularly for those with AN with
bulimic features [10,13,14,16]. For example, Root et al.(2010b) found that women with AN, BN and a lifetime
diagnosis of AN and BN (ANBN) all had increased risk
of substance use compared with controls, with ED sub-
groups with bulimic features being at increased risk for
alcohol use/dependence compared with the restricting
AN group (R-AN), and the R-AN group having similar
levels of illicit drug use as the binge/purge AN group
[14]. Baker et al. (2010) found no significant difference
in prevalence rates of SUD between AN patients and pa-
tients with BN, however this study did not differentiate
between AN subtypes [16]. Root et al. (2010a) found that
substance abuse/dependence was most common among
those with a lifetime diagnosis of AN and BN (ANBN),
least common among those with restricting AN, and the
presence of purging behaviour was more highly associ-
ated with SUDs than non-purging behaviour [13]. Thus,
substance use by patients with AN is more common
than previously thought, ED patients with bulimic fea-
tures appear to be at highest risk for alcohol use disor-
ders, and evidence for prevalence of drug use amongst
R-AN patients is mixed. Some studies have documented
specific associations between eating disorder sub-types
and varying patterns of substance use, but data is
inconsistent.
Substances of abuse
Alcohol Alcohol abuse/dependence has been found to
be more common in those with BN, binge eating (BE),
or those with AN who engage in binging and/or purging
behaviour [17,18]. Dansky et al. (2000) reported higher
levels of alcohol dependence in women with BN com-
pared to those without, but found higher levels of alco-
hol abuse only when the presence of depression and
PTSD was controlled for, indicating that these condi-
tions may influence or mediate the relationship between
BN and alcohol abuse. They concluded that 31% of
women with BN also have a history of alcohol abuse and
13% have a history of alcohol dependence [19]. However
studies do differ. For example, Franko et al. (2005) re-
ported prevalence rates of 27% of lifetime alcohol use
disorder (AUD) in their sample of ED patients. Levels of
alcohol abuse/dependence did not differ significantly in
those with AN compared with BN. However, of the AN
group reporting an AUD 72.7% were AN binge purging
type, which may explain this difference. Krug et al.
(2008) found no significant difference in lifetime and
current alcohol use between ED patients and a healthy
control group [11,20]. Within the ED group, those with
a diagnosis of Eating Disorders Not Otherwise Specified
(EDNOS) had higher levels of current and lifetime alco-
hol use compared with other ED types, including BN
[11]. This can be explained by the fact that many studies
do not include patients diagnosed with EDNOS. This
underscores the need for research on this commonly
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that alcohol abuse/dependence is more commonly found
in ED subgroups with bulimic features.
Where differences have been found, binge drinking
(associated with alcohol abuse) seems to be more highly
associated with BN than frequency of use (associated
with alcohol dependence). In a recent study, Piran and
Robinson (2011) found in a non-clinical sample that the
cluster of binging, dieting and purging behaviour was
most strongly associated with binge drinking (and co-
caine use) but not with the frequency of alcohol use
[21]. Stewart et al. (2000) also found that dietary re-
straint was associated with the quantity of alcohol con-
sumption (binge drinking) in women with BN, but not
with the frequency [22].
Several hypotheses have been suggested to explain this
differential relationship. Alcohol abuse and the ED may
be part of more general behaviour dysregulation includ-
ing impulsivity. Alcohol could be used as a form of emo-
tional regulation in ED women. Alternatively, increased
binge drinking may be the result of attempts to restrict
alcohol intake (because of the high calorie levels in alco-
hol) followed by alcohol binges [18,22]. Studies have
shown that restriction of a substance such as food or al-
cohol leads to increased reinforcement value for that or
other substances [23].
Alcohol use may also be a risk factor for the develop-
ment of an eating disorder [24,25]. Some studies have
indicated an increased prevalence of ED behaviours in
adolescents using alcohol, with frequency and severity of
alcohol consumption found to be positively associated
with number of ED symptoms [24]. Similarly, Piran and
Gadalla (2006), in a nationally representational study of
Canadian women, reported an association between risk
for developing an eating disorder and lifetime alcohol
dependence [26]. In contrast, Franko et al. (2005) found
that having an ED was more likely to lead to the devel-
opment of an AUD than the reverse. They report de-
pression and over concern with body image and
vomiting as the main risk factors for developing a co-
morbid AUD in women with AN [20]. The latter study
includes patients diagnosed with an ED, rather than risk
for ED or subclinical ED symptoms. This may explain
the greater impact of EDs on SUDs reported by Franko
et al. (2005), in contrast to the inverse relationship sug-
gested by the previous two studies. Further investigation
of the pathobiological and temporal relationship between
these two disorders is needed.
Caffeine and tobacco Caffeine is used as an appetite
suppressant or to provide energy and can be consumed
through coffee or diet drinks [8]. Similarly, tobacco is
used as a weight loss aid, not only because it suppresses
appetite, but because it can help to distract fromthoughts about food [8]. Distorted body image is associ-
ated with increased risk of a caffeine abuse disorder and
tobacco use has been associated with greater levels of
eating disorder pathology [8,13,16].
Baker et al. (2010) reported in their study that caffeine
and tobacco were the most frequently used substances,
and women with AN were more likely to have a caffeine
disorder and to smoke cigarettes (26% and 52% respect-
ively), compared with those with BN (23% and 45%).
However, this difference was found to be non-significant
and AN in this study was broadly defined. [16]. Krug
et al. (2008) reported that women with an ED (particu-
larly those with BN or AN-binging/purging type) were
more likely to smoke, and smoked more frequently as a
way of controlling weight, than healthy controls [11]. In
contrast, Root et al. (2010b) reported no difference in
levels of tobacco use across AN subtypes, including an
AN and BN lifetime group [14]. Thus, tobacco and caf-
feine use is greater amongst ED patients compared with
controls but reported prevalence rates across ED sub-
groups are somewhat inconsistent.
Illicit substances (amphetamines/stimulants/cannabis/
opiates) Amphetamines may be used as appetite sup-
pressants in order to aid weight loss [15,16]. Psychoactive
substances may also be used to help regulate painful affect
[27]. In a review of the literature, Holderness et al. (2004)
found that rates of amphetamine use were found to be
higher in patients with AN compared with BN [17]. Piran
and Robinson (2006, 2011) found associations between
dieting and purging behaviour (without binging) and
amphetamine use [18,21]. An association has previ-
ously been shown between dieting and bingeing and
amphetamine use, however Calero-Elvira et al. (2009) did
not find increased use of these classes of substance in their
ED group (combined BN, BED and AN) compared
with the general population [15]. Amphetamine use
may therefore be associated with dieting and purging
behaviour rather than binging behaviour, which might
be expected given its role in aiding weight loss, however
data is inconsistent. A recent study by Jeffers et al. (2013)
reported on the wide use of prescribed stimulants
(usually used in the treatment of ADHD) as weight loss
aids in a group of 705 undergraduate students [28].
Calero-Elvira et al. (2009) reported increased preva-
lence of cannabis and opiates in those with an ED (sub-
groups combined) compared with controls, however AN
restricting type did not demonstrate significant com-
bined drug use compared to controls [15]. Root et al.
(2010) found increased cannabis use in ED patients
compared to a control group and reported comparative
prevalence rates across ED subgroups for this class of
substance. They further reported that cannabis was the
most frequently used drug among AN patients, and
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population where cannabis was the most frequently used
illicit substance [14]. Calero-Elvira et al. (2009) postu-
lated that this class of illicit substances may be also be
used to cancel out the restlessness associated with
stimulant use [15]. In sum, illicit drug use seems gener-
ally more common in ED populations compared to
healthy controls; they may be used as weight-loss aids,
to regulate affect or to counteract the effects of other
substances. More data is needed to clarify differential re-
lationships between the types of illicit drugs and ED
subgroups.
Over the counter or prescription medications (laxatives/
diuretics/diet pills/thyroid medications/insulin) Laxa-
tives are used as a means of weight loss. They are thought
to be the most commonly abused substances by those with
an eating disorder, with prevalence rates of up to 75% be-
ing reported in this population [12]. According to Mitchell
et al. (1997), ED patients who misuse laxatives have higher
levels of co-morbid psychopathology than those who do
not, leading to treatment complications [12]. Pryor et al.
(1996) found that laxative use predicted higher levels of
perfectionism and avoidant personality traits [29]. Bryant-
Waugh et al. (2006) reported that 26.4% of their sample of
201 outpatients with an eating disorder diagnosis used lax-
atives as a means of losing weight, and these patients were
identified as having more severe clinical presentations
(eating disorder symptomatology and other psychopath-
ology) that were independent of the ED type [30].
Stimulant type laxatives are most commonly used and
desensitization leads to increased levels of usage in indi-
viduals [12]. Laxative misuse has been found to be an in-
effective weight-loss mechanism, and the abuse of
laxatives results in medical complications such as
chronic diarrhea, disturbances in electrolyte and acid–
base balance, reflex peripheral edema, constipation,
impairment in colon functioning and nephrolithiasis
(kidney stones), among others [12,31,32]. An association
has been found between laxative use and use of diuretics
and diet pills, however diet pills are less frequently used
compared with laxatives [12,33]. Diuretics are commonly
used as a method of purging in patients with BN, often
resulting in severe electrolyte imbalances [34]. The use
of multiple forms of purging methods has been associ-
ated with increased eating disorder severity, whereas
purging frequency has been shown to predict other forms
of psychopathology such as depression, impulsivity, anx-
iety and personality disorders [35]. ED patients may also
abuse thyroid replacement hormones in order to increase
metabolism and support weight-loss, leading to increased
risk for cardiovascular and metabolic problems, diabetes
and hypertension [36]. Patients with diabetes may also re-
duce or manipulate insulin use (particularly after bingeeating) in order to facilitate weight loss through calorie
loss [36,37] (Additional file 1: Table S1).
Aetiological and risk factors
The aetiological factors contributing towards co-morbid
eating and substance abuse disorders are best under-
stood from a biopsychosocial perspective. Aetiological
theories of co-morbidity include biological (e.g. genetic
and familial risk factors), addiction and behavioural
models, underlying personality factors (such as chronic
dysregulation, increased impulsivity and novelty seek-
ing), other co-morbid psychopathology, as well as envir-
onmental factors [7,10].
Biological factors Biological models implicate common
disturbances in neurotransmitter function in dopamine,
serotonin, gamma aminobutyric acid, and endogenous
opiate systems across both EDs and SUDs [7,38]. Evi-
dence for this model includes the similarity in physical
symptoms across these disorders and the links that have
been shown between food deprivation and the increased
“biologically reinforcing effects of substances” [7].
With regards to an inherited genetic predisposition,
studies have shown independent genetic heritabilities for
SUDs and EDs, however, there is insufficient evidence
from either twin or family studies for a shared genetic
link [7,14,16,39]. With regards to twin studies, Kendler
and colleagues (1995) researched the genetic and envir-
onmental risk factors for six psychiatric disorders in-
cluding BN and alcohol abuse. They concluded that
vulnerability for BN and alcohol abuse was influenced by
separate genetic factors. While BN may share risk factors
with other psychiatric disorders, the majority of genetic
factors affecting risk for alcohol abuse are specific to the
disorder. In addition, co-morbidity was affected by a
combination of genetic and environmental (family and
individual) influences [40]. Wade et al. (2004) found, in
one twin study, that psychoactive substance use but not
abuse or dependence was associated with increased risk
for BN in the other and concluded that the frequent co-
morbidity between BN and SUDs was not due to shared
familial risk factors, but a combination of genetic and
environmental influences. They further reported that
risk for BN was only associated with risk for neuroticism
and novelty seeking in male siblings. Further, novelty-
seeking was associated with psychoactive substance use
in this subgroup. They suggested that there may be a fa-
milial predisposition with respect to BN and novelty
seeking in men, which may manifest in psychoactive
substance use [41]. Baker et al. (2010) reported signifi-
cant co-variance between EDs and SUDs which may be
attributable to environmental and/or genetic factors, but
identified genetic factors as the more important con-
tributor to the overlap [16]. Similarly, Slane et al. (2012)
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bulimic behaviours (particularly compensatory behaviours,
followed by binge eating) and co-morbid alcohol use, pro-
viding evidence for genetic or heritable links between
these two types of disordered behaviour [42].
Considering family studies, Lilenfeld et al. (1998)
found no common familial link between BN and sub-
stance use disorders [43]. Redgrave et al. (2007) reported
higher rates of binging, vomiting, laxative and diet pill
use across the lifetime, increased ED psychopathology
(i.e. higher scores on several domains of the Eating
Disorders Inventory −2), and higher rates of alcohol
use amongst ED patients with a first-degree relative
with an alcohol abuse disorder compared to those
without. The authors concluded that having a first degree
relative who abused alcohol was likely to exacerbate
(rather than cause) ED psychopathology [39].
Addictions model The addictions model purports that
both EDs and SUDs are based on chemical dependency
with similar genetic, familial, personality and socio-
cultural influences [7]. Goodman (1990, 2008) provided
evidence in support of the hypothesis that addictive dis-
orders, including psychoactive substance abuse and BN,
have a common, underlying biopsychological process,
which includes neurobiological as well as personality fac-
tors. According to this hypothesis, the addictive process
involves difficulties in three functional systems, namely
motivation-reward, affect regulation and behavioural in-
hibition. Impairment results in various behavioural man-
ifestations such as BN or SUDs [44,45]. Speranza et al.
(2012) investigated the extent to which ED patients
(without co-morbid SUDs) met Goodman’s (2008) diag-
nostic criteria for an addictive disorder. They reported
that participants with BN met the same proportion of
diagnostic criteria as a group with a SUD only (65% vs.
60% respectively). This proportion was significantly higher
than those met by the AN-restricting (R-AN) group but
not the AN-purging (P-AN) group. No significant correl-
ation was found between impulsivity and addictive person-
ality traits with an addictive ED [46]. Cassin and von
Ranson (2007) similarly investigated the association be-
tween BED and addictive disorder. They reported that
92.4% of their sample met the DSM-IV criteria for sub-
stance abuse/dependence, and 40.5% met Goodman’s
(1990, 2008) criteria, which they concluded to be insuffi-
cient evidence to reclassify BED as an addiction [47].
Personality factors Evidence from the genetic/familial
and addiction models suggests that underlying personal-
ity vulnerability factors should be further considered as a
potential common causal mechanism for co-morbid EDs
and SUDs. Personality vulnerability factors appear to dif-
fer depending on the ED subtype [7]. Krug et al. (2009)found an association between family history of alcohol
abuse/dependence and highest prevalence of substance
use in ED patients with bulimic features and high nov-
elty seeking behaviours. They propose that novelty seek-
ing is a genetically inherited personality trait which
predisposes patients to these co-morbid disorders [10].
Similarly, Lilenfeld et al. (1997) reported increased rates
of alcohol dependence, drug abuse and dependence (as
well as panic disorder, social phobia and Cluster B per-
sonality disorders) in first-degree relatives of women
with co-morbid BN and substance dependence com-
pared with the first-degree relatives of women with BN
without substance dependence. They concluded that
anxiety, impulsivity and affective instability may indicate
a predisposition for co-morbid BN and substance de-
pendence [48]. In sum, twin and family studies generally
do not support a shared genetic link for co-morbid EDs
and SUDs, however some evidence suggests that this co-
morbidity may be mediated by personality traits such as
novelty seeking, which itself may be an inherited trait.
Broad personality sub-types have previously been re-
ported among adolescents and adults with EDs and in-
clude (i) high functioning, (ii) emotionally dysregulated,
(iii) avoidant/insecure, (iv) constricted/obsessional and
(v) behaviourally dysregulated [49]. Findings have been
variable regarding the aetiological role of emotional
and behavioural dysregulation. Thomson-Brenner et al.
(2008) found that the onset of co-morbid substance
abuse was most highly associated with the behaviourally
dysregulated personality subtype (usually associated with
BN), but that ongoing substance abuse was better pre-
dicted by previous history of SUD [50]. In contrast how-
ever, Benjamin and Wulfert (2005) demonstrated that
higher levels of emotional dysregulation were found in
those with co-morbid binge eating and alcohol abuse,
and impulsivity and anti-social traits were associated ra-
ther with either binge eating or alcohol abuse [51]. Slane
et al. (2013 –in press) found evidence for increased rates
of bulimic symptoms and alcohol use difficulties over
time in patients with a personality profile characterized
by both emotional lability and behavioural dysregulation
[52]. Krug et al. (2009) reported an association between
novelty seeking and substance use in both those with
AN binging/purging type and in those who moved from
an AN to a BN diagnosis. The researchers were not able
to demonstrate differences between these sub-groups
[10]. Current evidence overall, although somewhat in-
consistent, more commonly points to an association be-
tween underlying personality vulnerability factors and
EDs with bulimic features compared with EDs without
these features.
Davis and Claridge (1998) researched the extent to which
addictive personality traits explained the co-morbidity be-
tween EDs and SUDs. They found similar levels of
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their sample compared with those previously reported for
patients with SUDs. Both ED subgroups were found to have
high levels of neuroticism (emotional reactivity, negative
affect), which was strongly associated with addictiveness.
However for the BN group, addictiveness was also associ-
ated with impulsivity and anti-social traits, whereas for
those with AN it was associated with introversion [53].
Wilson (2010) argued that there was insufficient support
from epidemiological, laboratory, genetic and familial and
treatment outcome studies to clinically validate the addic-
tions model [54]. Thus, although there is evidence that some
ED patients (particularly those exhibiting binging/purging
behaviour) experience their ED as an addiction, evidence
for shared addictive personality characteristics is inconsist-
ent and overall there appears to be insufficient empirical
evidence in support of the addictions model [7,54,55].
Other psychopathology A related potential mediating
factor in the relationship between EDs and SUDs is
Attention Deficit Hyperactivity Disorder (ADHD). ADHD is
characterized by impulsivity, hyperactivity and inattention,
symptoms related to the personality factors previously de-
scribed, and often present in patients with EDs. Studies have
reported co-morbidity between ADHD and EDs and SUDs
respectively [56-58]. Kollins (2008), in a review of the litera-
ture, reported that co-morbid EDs and ADHD increased
the risk for a SUD [57]. Strongest associations have been
found between ADHD and EDs with binging behaviours
(i.e. BN, BED and EDNOS) [56,58]. The hypothesised patho-
logical mechanisms explaining this co-morbidity include
underlying impulsivity and shared genetic risk factors such
as neurobiological dysfunction in reward systems [56,58].
With regards to ADHD and substance abuse, Sobanski et al.
(2010) identified emotional lability as a predictor of ADHD
severity (particularly hyperactivity-impulsivity symptomotol-
ogy) as well as SUDs in children [59]. ADHD is therefore an
important potential mediator and/or aetiological factor in the
relationship between EDs and SUDs.
A lifetime history of depression has also been identi-
fied as a common underlying factor for EDs and SUDs
[60]. Dansky et al. (2000) identified PTSD and MDD as
mediating factors in the relationship between BN and al-
cohol use disorders [19]. Similarly, Measelle et al. (2006)
in their sample of adolescent females found that (i) de-
pressive symptoms predicted higher future levels of both
eating pathology and substance abuse and (ii) that eating
pathology predicted increased future substance abuse
but not the inverse. They hypothesised that both path-
ologies may serve to regulate weight-loss and mood, and
distract from negative affect [61].
Environmental factors Environmental factors may im-
pact on the predisposition towards this co-morbidpsychopathology. Cumulative childhood trauma can lead
to multiple forms of dysregulation, often culminating in
psychopathology (including eating disorders and sub-
stance abuse disorders) in adolescence or adulthood
[62,63]. Baker et al. (2007) identified an association be-
tween childhood sexual abuse and co-morbid BN and a
SUD [60]. Corstorphine et al. (2007) also found an asso-
ciation between childhood trauma (particularly child-
hood sexual abuse) and co-morbid substance abuse in a
group of ED patients (across ED subtypes, but with a
non-significant trend of lower rates in the restrictive AN
subgroup). They hypothesised that childhood trauma
leads to increased impulsive behaviour, including multi-
impulsivity (i.e. BN with concurrent impulsive behav-
iours such as substance abuse) [64]. However, this
relationship appears to be varied and complex, as Rorty
et al. (1994) reported that in their sample of BN patients,
SUDs were marginally associated with childhood psycho-
logical and physical (but not sexual/multiple) abuse only
in the presence of a co-morbid personality disorder [65].
The presence of childhood trauma is therefore an import-
ant aetiological factor to consider, especially within ED
subgroups with bulimic features.
Parental factors associated with co-morbidity include
lower parental educational levels, closer maternal rela-
tionships, parental modeling of substance abuse or eat-
ing disordered behaviours, and maternal emphasis on
weight and appearance [8,9,66].
Summary The overall conclusion is that current re-
search indicates separate aetiologies and courses for
each disorder [7,23,67]. Given the lack of causal evi-
dence, it may be more appropriate to talk about risk fac-
tors for the development of co-occurring ED and SUD
and to focus research and clinical efforts on the early
identification of individuals at risk for this comorbidity.
In considering risk factors for co-morbid EDs and
SUDs, developmental processes of adolescence need to
be mentioned. Adolescence is associated with increased
susceptibility to socio-cultural pressures towards thin-
ness and for and risk-taking behaviour including sub-
stance use [8,23]. It is a period involving, among others,
increases in appetite, sensation seeking behaviour, emo-
tional reactivity, saliency of social status, parent–child
conflict, depression and anxiety [68]. Thus increased so-
cial and emotional challenges occur within the context
of reduced parental support and immature coping mech-
anisms. All of this occurring while rapid neurobiological
changes are taking place, leaving adolescents vulnerable
to unhealthy experimentation or experiences developing
into psychopathology [68]. For example, Stock et al.
(2002) reported that female adolescents with an ED with
purging symptoms used substances in order to relax/im-
prove mood, manage anger, avoid problems and control
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found in adolescents reflect these developmental chal-
lenges and highlight the importance of accurate assess-
ment and intervention for this population [9,24,61,70].
Assessment and diagnosis
Substance use and substance abuse disorders are compli-
cating factors in the assessment, diagnosis and manage-
ment of EDs. Research has shown that ED patients who
abuse substances demonstrate worse ED symptomatol-
ogy and poorer outcomes than those with EDs alone,
and that the presence of an ED in SUD patients leads to
greater severity of substance abuse and poorer functional
outcomes [4,50]. Sequelae of co-morbidity include severe
medical complications [5], longer recovery time from
the ED (and/or the SUD) [6,20,71], poorer functional
outcomes [4,6], more frequent and/or severe psychiatric
co-morbidity [4,6,71], higher rates of suicide/suicide at-
tempts [1,6] and higher mortality rates [72,73]. Further,
recent findings suggest that clinicians should be vigilant
about the possibility of suicidality in individuals with BN
and SUDs because their suicidality risk may be higher
than that explained by the SUD alone. Assessing for
the presence of suicidality and the level of risk and the
temporal order of suicidality, ED and SUD is, therefore,
critical [1].
The strongest message conveyed in the current litera-
ture is the importance of screening and assessment for
co-morbid SUDs and EDs in patients presenting with ei-
ther disorder [12,74,75]. Once a co-morbid disorder has
been identified, a full medical and psychiatric evaluation
is recommended, and in the case of AN, patients may
need to be medically stabilized before therapeutic treat-
ment can commence for both disorders [8]. One of the
challenges to diagnosis is that both ED and SUD patients
are often treatment resistant and may experience shame
and/or guilt, leading to reluctance to report ED or SUD
symptoms [8,12,75]. Drug and alcohol use can also have
an influence on features that are more specific to the as-
sessment of EDs, such as weight, appetite and dietary re-
striction, thus complicating the diagnostic process [75].
Collateral information is therefore key when assessing
patients with EDs, while the importance of a direct but
non-judgmental approach during assessment is also em-
phasized [12,74].
The use of standardized screening or assessment ques-
tionnaires is advisable [75,76]. Such screening tools
could be used for assessing risk for both disorders in
primary care [74]. Black and Wilson (1996) found the
Eating Disorder Examination – Questionnaire (EDE-Q)
to be a valid screening tool to identify ED symptoms
amongst a clinical sample of substance abuse patients,
particularly for diagnosing BN and identifying low level
ED behaviours where further assessment is indicated[77]. For a review of screening tools for the risk/presence
of EDs see Grilo et al. (2002) [76]. According to Conason
et al. (2006) brief screeners for the presence of alcohol
abuse/dependence designed for use in primary care set-
tings include the CAGE questionnaire (cut down,
annoyed, guilty, eye opener) and the TWEAK test (toler-
ance, worried, eye-opener, amnesia, cut-down) [74,78,79].
Longer instruments include the Michigan Alcoholism
Screening Test (MAST) and the Alcohol Dependence
Scale (ADS) [80,81]. Conason et al. (2006) also recom-
mend the following screening tools for the presence of
other substance disorders: the Drug Abuse Screening
Test (DAST); the Two Item Alcohol and Drug Screening
Questions; and the Drug Screening Questionnaire (DSQ)
[74,82-84].
Conason et al. (2006) have argued that interviewing is
the most effective assessment technique for diagnosing
co-morbid EDs and SUDs [74]. They recommend taking
a detailed substance abuse history, including current and
lifetime substance use and periods of greatest severity.
Such a history should also incorporate detailed informa-
tion on the function and patterns of substance use.
Questions should specifically explore the misuse of sub-
stances as weight loss mechanisms, for example, caffeine,
tobacco, insulin, thyroid medications, stimulants or over
the counter medications (laxatives, diuretics) used for
metabolism restriction, caloric restriction, appetite
suppression or purging [11,36,37]. Similarly, the role
of alcohol or psychoactive substances in emotional
regulation should be explored, for example, the use of
alcohol, opiates or cannabis for the relief of anxiety, depres-
sion, guilt or shame, or for emotional reward [27]. Wolfe
and Maisto (2000) highlight the importance of a behavioural
assessment (including questionnaires, self-monitoring,
role play and collection of collateral information) in
order to explore the functional relationship between
substance use patterns and ED behaviours. Precipitants,
concomitant affective states and consequences of each
set of behaviours should be considered as this will aid teasing
out specific risk factors as well as an understanding
of the mutual influence of behaviours and emotional
states [23].
While the current psychiatric nosology for EDs utilises
a symptom based approach, recent research has also fo-
cused on an alternative classification system for EDs
based on co-morbid psychopathology and associated fea-
tures [3]. The proposed classification systems include (i)
dietary versus dietary-negative affect EDs (where the ED
is characterized by either dietary restraint, negative affect
or a combination of both), (ii) under-controlled versus
over-controlled EDs (which considers patterns of mood
disturbances, anxiety and impulsivity) and (iii) low psy-
chopathology EDs [3]. Such a diagnostic approach may
provide a structured way of assessing risk factors,
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patients.
The following section considers the management of
co-morbid EDs and SUDs including an outline of differ-
ent treatment modalities.
Management
Some of the pertinent questions in the treatment of co-
morbid EDs and SUDs include how to ascertain the
presence of a co-morbid disorder, whether to treat the
disorders concurrently, and if not, which disorder to ad-
dress first [12,76]. One difficulty is that treatment stud-
ies for EDs and SUDs often exclude patients with dual
diagnoses making research evidence on effective man-
agement strategies for this population extremely scarce
[12,85]. Nevertheless, there are a number of important
considerations. Firstly, sequential treatment may lead to
an increase/relapse of symptoms of one of the disorders
as symptoms of the other disorder improve [4,8,86]. Sec-
ondly, symptoms of the disorder not being treated may
interfere with recovery from the disorder for which
treatment is underway [87,88]. Thirdly, inadequate man-
agement of both disorders can also increase relapse rates
in symptoms of one or both [8,86]. An additional con-
sideration is the presence of other co-morbid psychiatric
diagnoses such as anxiety and depression which may
need to be simultaneously managed in these patients [4].
Despite the paucity of treatment outcome studies,
some researchers suggest that treatments which target
aetiological factors common to both disorders are effect-
ive, for example addressing difficulties with emotional
regulation in concurrent binge eating and substance use
disorders [89]. Woodside and Staab (2006) recommend
that when there is a current SUD, patients should
undergo detoxification prior to ED treatment, and where
possible this should be combined with ED treatment, for
example in a residential treatment facility [90]. Overall,
the literature indicates that the ED and SUD should be
addressed simultaneously [4,76,86]. CASA (2003) rec-
ommend programmes which include treatments focused
on substance abuse and EDs specifically, as well as indi-
vidually tailored combinations of personal, group and
family therapy provided by a multi-disciplinary team [8].
General treatment principles for eating disorders such as
establishing a trusting, collaborative therapeutic relation-
ship and avoiding power struggles should be followed
[91]. Several treatment modalities are considered below.
Medical stabilisation
Patients with AN with particular medical indications
such as critically low BMI, blood chemistry imbalances,
dehydration, irregular cardiac function and heart rate
and blood pressure abnormalities, may require hospital-
isation and/or nutritional rehabilitation [92,93]. The rateand severity of change in physiological functioning are
important to consider, for example less severe but rapid
changes may necessitate hospitalization [93]. For pa-
tients with AN, weight restoration may be important
prior to the commencement of psychological treatment
because the effects of starvation on affect and cognition
can interfere with therapy [93].
ED patients who abuse laxatives require immediate laxa-
tive withdrawal because of the physical danger of laxative
abuse, and the increased risks of mortality [94]. Manage-
ment recommendations include immediate cessation of
laxative use and medication to promote bowel function if
necessary, encouragement of high fibre intake and exer-
cise, and psycho-education. Psycho-education should
cover aspects relating to the physiological effects of laxa-
tive abuse, the effects of laxative withdrawal, the physi-
ology of normal bowel functioning and cognitive
distortions surrounding laxative use, including that it does
not result in weight loss [12,94]. Alternatively, (and espe-
cially for patients with a flaccid bowel), stimulant laxatives
may be replaced by osmotic laxatives such as lactulose to
promote bowel function [12,94]. Once all laxatives have
been discontinued, a programme of desensitisation to
laxative use may be implemented [94]. Colton et al. (1999)
have reported a success rate of 57% short to medium term
laxative abstinence in their sample following an inpatient
laxative withdrawal programme [94].
Pharmacotherapy
Research indicates that pharmacotherapy alone should not
be the primary treatment for AN [76,95], however anti-
depressants (particularly SSRIs) have been effectively used
to treat both BN patients as well as patients with an alco-
hol use disorder with co-morbid major depression
[38,76,95]. Some evidence has also been found to support
the use of opioid antagonists in the treatment of both EDs
and AUDs [38]. Pharmacotherapy may be indicated in
combination with therapeutic interventions [8].
Psychological treatments
Various psychological interventions have been used in
the treatment of co-morbid EDs and SUDs, ranging
from individual to group and family therapy. Common
features across interventions include psycho-education
regarding the aetiological commonalities, risks and
sequelae of concurrent ED behaviours and substance
abuse, dietary education and planning, cognitive chal-
lenging of eating disordered attitudes and beliefs,
building of skills and coping mechanisms, addressing
obstacles to improvement and the prevention of re-
lapse [76,89,96].
There is evidence for the efficacy of various forms of
CBT, including self-help CBT programmes, in the treat-
ment of EDs (particularly BN), however the efficacy of
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amined [8,74,76,86,95,97-99]. Sinha and O’Mally (2000)
and Grilo et al. (2002) nevertheless suggest that for the
treatment of EDs and alcohol abuse, a CBT approach
which targets both pathogenic eating behaviours as well
as alcohol use is likely to be effective [38,76]. They iden-
tify particularly useful strategies such as self-monitoring,
identification of high risk situations and coping skills to
manage emotions or situations which may trigger loss of
control. Often a “stepped-care” approach is recom-
mended where patients begin with self-help CBT and if
necessary proceed to guided self-help interventions or to
group or individual therapy [100].
Motivational interviewing (MI) can be used prior to
CBT intervention and aims to increase the likelihood of
a patient engaging with and continuing therapy by im-
proving insight into the problem, building commitment
and increasing intrinsic motivation for change [100]. MI
combined with therapist-client feedback regarding the
progress of symptom improvement (compared to the
norm) and difficulties with achieving target behaviours is
called motivational enhancement therapy (MET), and
can be used as an individual or adjunctive treatment
[100]. Dunn et al. (2006) report mixed evidence for
MET in the treatment of EDs. They found that one ses-
sion of MET used as an adjunct to a CBT self-help
programme in a group of patients with BN or BED led
to increased readiness to change bingeing behaviours,
but did not lead to change in eating attitudes, frequency
of bingeing and compensatory behaviours or treatment
compliance [100]. No studies have examined the efficacy
of MET with co-occurring EDs and SUDs.
Dialectical behaviour therapy (DBT) has been investi-
gated as a treatment for co-morbid EDs and SUDs [76].
Grilo et al. (2002) suggest that DBT, even when not fo-
cusing on ED behaviour specifically, may reduce ED
symptoms in patients with BN and BED, because it teaches
emotional regulation strategies and coping behaviours, and
these disorders have been associated with emotional and
behavioural dysregulation [76]. Courbasson et al. (2012),
in a study comparing the efficacy of DBT with treatment
as usual (TAU) (which consisted of a combination of
motivational interviewing, CBT and relapse prevention
strategies) for patients with co-morbid EDs and SUDs, re-
ported improved retention rates for the DBT group com-
pared with the TAU group (87% vs. 20% post-intervention
and 60% vs. 20% at 3- and 6- month follow-ups) [85].
Their results also provide preliminary positive evidence
for cognitive and behavioural treatment outcomes in the
DBT group, including improved ED behaviours and
attitudes, reduced rate and severity of substance use,
greater regulatory capacity for negative emotions and
improvement in depressive symptoms. Nearly all improve-
ments were present post-intervention and sustained at3- and 6- month follow-up [85]. Courbasson et al. (2011)
reported similar results for the use of mindfulness-
action based cognitive behavioural therapy (MACBT)
(which includes teaching mindfulness and mindful
eating, increasing emotional regulation skills, provid-
ing psycho-education, encouraging balanced physical
activity and focusing on strengths) for a group of
patients with BED and co-morbid SUDs. They describe
fewer objective binge eating episodes, reductions in
severity of drug addiction and improvements in disor-
dered eating attitudes and depressive symptoms post
treatment [89].
Some researchers also report efficacy of 12 step pro-
grammes for the treatment of SUDs, especially alcohol
abuse/dependence [12,87]. Such programmes could run
concurrently and work effectively with ED treatment
[87]. Long term individual psychotherapy has also been
recommended in the treatment of co-morbid EDs and
SUDs, however, this is thought to be more appropriate
once recovery from SUD has been maintained for a
period of time. CBT type therapies are recommended
during or after substance use recovery treatment [87].
Additional treatments that are recommended for EDs
include cognitive analytic therapy, interpersonal psycho-
therapy, focal psychodynamic therapy and family therapy
(especially for adolescents) [8,92,93,95].
Inpatient vs. outpatient treatment
The 2004 NICE clinical guidelines indicate that where
possible ED patients should be treated on an outpatient
basis for at least 6 months, except where severe co-morbid
substance abuse is likely to interfere with outpatient
treatment efficacy [95]. Indicators for hospitalisation,
partial hospitalisation, residential or intensive outpatient
treatment may depend on general medical and psy-
chiatric complications (such as depression or suicid-
ality), symptom severity and previous course of the
illness [92].
Franko et al. (2005) found that both inpatient and out-
patient treatments were effective at addressing AUD in pa-
tients with an ED [20]. Residential treatment programmes
have been found to be effective in the treatment of AN
and BN both post-treatment and at 3–4 year follow-up
[101,102]. Treatment for EDs may also take place within
substance abuse treatment programmes, however not all
such programmes are equipped with adequate knowledge
or resources [93]. Killeen et al. (2011) found that of the ad-
diction treatment centres in their sample that screened for
the presence of EDs, 67% of centres reported that they
admit low level ED patients, and 21% reported that they
treat EDs [75]. Where inpatient or residential treatment is
preferred, follow-up treatment in the form of individual or
group therapy, support groups or 12 step programmes is
vital to preventing relapse of both disorders [87,93].
Gregorowski et al. BMC Psychiatry 2013, 13:289 Page 10 of 12
http://www.biomedcentral.com/1471-244X/13/289Conclusion
SUDs are prevalent in patients with EDs and are more
commonly seen in ED patients with bulimic features.
Substances of abuse range from alcohol to illicit drugs as
well as over the counter or prescribed medications. Al-
cohol and psychoactive drugs may be used for emotional
regulation or as part of a pattern of impulsive behaviour.
Caffeine, tobacco, laxatives, stimulants, thyroid medica-
tions and insulin may be misused as weight-loss aids.
While EDs and SUDs have shared and associated fea-
tures and risk factors, the literature indicates a number
of distinct differences in the aetiology and course of both
disorders. The importance of screening ED patients who
present for treatment for SUDs, and visa versa, is em-
phasized in the literature. The functional relationship
between the ED and substance of abuse varies across ED
subtypes and needs to be carefully assessed. There is a
paucity of treatment studies for the management of co-
morbid EDs and SUDs, however, the available literature
suggests that where possible, both disorders should be
treated simultaneously using a multi-disciplinary approach.
The need for hospitalization or inpatient treatment
depends on general medical and psychiatric consider-
ations. Patients may need to be medically stabilized
before therapeutic treatments are employed. Emphasis
should be placed on building a collaborative therapeutic
relationship. While CBT has been frequently used in the
treatment of co-morbid EDs and SUDs, there are no ran-
domized controlled trials of its use in this context. More
recently evidence has been found for the utility of DBT in
reducing both ED and substance use behaviors, with these
improvements sustained over time.
This review provides a broad overview of the preva-
lence, aetiology, assessment and management of co-
morbid EDs and SUDs. It integrates and discusses
current research and attempts to delineate the functional
relationship between ED subtypes and various substance
use/dependence/abuse. It is by no means exhaustive and
future research would benefit from a meta-analysis of all
the current research in order to better understand the
relationships between these two commonly co-occurring
disorders.
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